PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy dlvr.it/TKmcY4

We are pleased to announce that Dr. Cynthia Ma has been elected as President-Elect of CAHON. Congratulations, Dr. Ma! The President-Elect will serve a one-year term beginning on June 1, 2025, and will automatically assume the role of President for the 2026–2028 term. Learn

It was an honor to speak tonight Chinese American Hematologist & Oncologist Network about next generation T cell therapies — an area where we’re seeing much progress but are really just getting started. Thank you to Liang Deng, MD PhD, Delong Liu, MD, PhD and Jing-Zhou Hou for the invitation to speak. I am so proud of the rapid

Also enjoyed hearing colleague Jedd Wolchok (Weill Cornell Medicine Meyer Cancer Center) give a wonderful talk Chinese American Hematologist & Oncologist Network on the importance of combination #immunotherapy strategies in overcoming resistance, and progress made thus far in this body of research.

Grateful for the opportunity to speak alongside Dr. Patrick Hwu Jedd Wolchok Dr. Lei Zheng Mays Cancer Center at UT Health San Antonio on the latest in cancer immunotherapy, thanks to a fantastic event co-organized by Chinese American Hematologist & Oncologist Network and jhoonline.biomedcentral.com

What a great night and wonderful talks by Drs. Patrick Hwu, Jedd D. Wolchok, Li Zheng, and Zihai Li at the CAHON-JHO CME event at ASCO. We are grateful for the support of our CAHON community from the leaders in the Immuno-Oncology field!

Deeply honored and grateful to receive the Young Investigator Award from Chinese American Hematologist & Oncologist Network! I’m continually inspired and thankful for the support, guidance, and opportunities provided by this incredible community. Truly proud to be part of it!

Last month, Memorial Sloan Kettering Cancer Center's interdisciplinary group that created MSK-IMPACT received the AACR Team Science Award in recognition of its significant contributions to fundamental cancer knowledge. Read more here: bit.ly/4eaZr1c

Register now for the 12th Annual New York Oncology Forum! 📅 Oct 4–5, 2025 | 📍 Flushing, NY 🎉 Celebrating 20 years of CAHON with cutting-edge sessions from #ASH, #ASCO, #SITC + a special Members-Only Gala! 🔗cahon.org/events/upcomin… #NYOF2025 #CAHON #Oncology #Hematology

Dr. Jeffrey Drebin, Chair of the Department of Surgery, has been named MSK's next Chief Physician Executive. He will succeed esteemed neuro-oncologist Dr. Lisa DeAngelis who will retire this summer. In this role, Dr. Drebin will lead all clinical services and research, medical

Congratulations to our graduating gap—year medical student fellows! What an amazing hard-working and collegial group. You have accomplished a lot in clinical research and learned a lot in clinical dermatology. Best of luck with the rest of your medical school journey and your

Congratulations to our youngest daughter Emma for finishing high school and entering college in the UK! Emma, we are so proud of you!

Congratulations to our son Daniel for finishing a busy and productive sophomore year at Emory. We both had the opportunity to attend the AACR in Chicago this Spring! Special thanks to Daniel’s research mentors at Weill Cornell, Sadna Budhu, Taha Merghoub, and Jedd D. Wolchok!

🚨 The FDA has approved the immunotherapy drug #pembrolizumab (Keytruda®) to be given before and after surgery for patients with #headandneck squamous cell cancer (#HNSCC) in combination with standard therapy. Dr. Nancy Lee, a radiologist oncologist at MSK, helped design the

📢 Register Now for CAHON’s Upcoming Events! Join the Chinese American Hematologist and Oncologist Network (CAHON) for two outstanding opportunities to stay informed and connected with the oncology community: July 22, 2025 – Post-ASCO Virtual Update 👉 Details & Registration:

The neoadjuvant (pre-surgery) use of combination immunotherapy as frontline treatment for high risk Stage III melanoma has been approved by the Pharmaceutical Benefits Advisory Committee (#PBAC) and will soon be listed on the #PBS and subsidised for all Australian patients.   The

📢 Exciting News from CAHON! We’re proud to announce that the Journal of Hematology & Oncology (JHO)—the official journal of the Chinese American Hematologist and Oncologist Network (CAHON)—has reached a new Impact Factor of 40.4, up from 29.9 in 2024. This places JHO in the top